A Study On Sales Model Transformation Research Of A Product Of G Company

With the deepening of China’s medical reform, pharmaceutical manufacturers ofpharmaceutical sales model is also constant innovation, the traditional pharmaceuticalsales model has not applied to modern pharmaceutical sales management activities.Therefore, according to the pace of the national health care reform, changes inpharmaceutical sales model has become a key enterprise promoting drug salesperformance. This article is for such research background, G Enterprises Apharmaceutical sales for a specific case study, the G A pharmaceutical sales businessmodel transformation issues a detailed analysis and discussion. In the course of the studyin this article, this paper analyzes in detail the main stages and characteristics of China ’spharmaceutical sales channel development, and on this basis, focusing on the outrightsales, sales agents, sales and distribution system cheap contract sales model and othercharacteristics and advantages and disadvantages. Laid the theoretical foundation for theresearch of this article. Based on the theoretical analysis above, this paper G Apharmaceutical company sales channels turned to specific research object, based on thestatus quo G A pharmaceutical sales company introduced the above, a detailed analysisof the drug under the current sales model the problems. Through this analysis whichshows that the current G A pharmaceutical company in terms of sales model existsprimarily Chuanhuo serious difficulties regional management, pharmaceutical saleschannel conflict is serious, pharmaceutical tender imperfect system and other issues. Forsuch problems, this article details from the external environment to the enterprise’sinternal environmental analysis of the effects of two factors G A pharmaceutical companyin sales model transformation. And for the results of the analysis presented in CompanyG A pharmaceutical sales model program, stressed the need to change the originalcancellation reserve price sales model into specialized business model, which sells goodsfactory direct sales business to a professional pharmaceutical company, and bymanufacturers co-investment with commercial companies to choose the way to thedealer. I hope through this study, effectively avoid G A pharmaceutical company salespolicy lowest risk, but also effectively reduces the pharmaceutical sales process intermediate links, to avoid channel conflict with each other changing products andbetween multiple operators and other issues. Improve the quality of pharmaceutical saleschannel management. Thereby effectively raising the G A drug company salesperformance.